The present disclosure relates to the pharmaceutical use of antagonists (e.g.,an antibody or antigen-binding portionthereof) that specifically bind to FAM19A5 to promote a blood vesselnormalization and treat a disease (e.g., cancer) in a subject inneed thereof, e.g., by promoting a blood vessel normalization.
